Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about European projects that are funded by European programmes including FP7, H2020, IMI, JNPD, AAL and EU Health. For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

"Stress and the aging brain: the interplay between genetic susceptibility, aging and psychosocial stress on early symptoms of dementia"

STAGED

As the population is growing older, the risk for dementia increases. The complexity of dementia calls for a multidisciplinary approach; in this project I will combine the research fields of Epidemiology, Genetics, Psychology and Cognitive Neuroscience. It is crucial to identify persons at risk for developing dementia, as possible treatment...

Funding Programme
Start Date
End Date
Total Funding
€ 136 064
European Countries Involved

A European DNA bank for deciphering the missing heritability of Alzheimer’s disease

EADB

Understanding the genetics of Alzheimer's disease (AD) is one of the best ways of improving our knowledge of the disease's underlying pathophysiological processes. Indeed, genetic factors account for up to 70% of the attributable risk in common forms of AD. The advent of genomic approaches has led to the characterization of 26 genetic determinants...

Funding Programme
Start Date
End Date
Total Funding
€ 3 644 713
European Countries Involved

A European multicentre double-blind placebo-controlled phase III trial of nilvadIpine in mild to moderate Alzheimer’s disease

NILVAD

Alzheimer’s disease (AD) is an ever-increasing public health concern among the aging population and is the most common form of dementia affecting more than 15 million individuals worldwide and around 5 million Europeans. The direct and indirect costs of AD and other dementias amount to more than €440,000 million each year (www.alz.org, 2010).Even...

Funding Programme
Start Date
End Date
Total Funding
€ 7 916 016

ACces to Timely Formal Care

ACTIFcare

In the absence of a cure for dementia, most research is aimed at an early diagnosis as it opens the way to timely future care and treatment, and can help people take control of their lives and plan ahead. However, people with moderate to severe dementia and their carers are often not receiving services of the type, quality and timing that they need...

Funding Programme
Start Date
End Date
Total Funding
€ 2 396 428
European Countries Involved

Aetionomy – Organising Mechanistic Knowledge about Neurodegenerative Diseases for the Improvement of Drug Development and Therapy

AETIONOMY

IMI’s Call 8 is geared to develop knowledge frameworks for ‘druggable mechanisms’ for two domains of pathophysiology. In response to this call, we propose (I) the development of a generic AETIONOMY pipeline to capture and infer over mechanistic knowledge of pathophysiology, and  (II) the focused application of this pipeline to derive clinically...

Funding Programme
Start Date
End Date
Total Funding
€ 17 546 060

Alterations in Memory Networks in Mild Cognitive Impairment and Alzheimer’s disease: Relating the Impact of Amyloid Burden with PIB-PET on Neuronal Activation as Assessed with fMRI

MCI_AD PIB-PET_FMRI

The main objective of this first 2-year period as a post-doctoral research fellow at BWH/MGH Harvard Medical School is to get training in novel Magnetic Resonance Imaging (MRI) and Pittsburgh Compound B–Positron Emission Tomography (PIB-PET) techniques, their analysis methods, and applications to aging and age-related neurodegenerative diseases...

Funding Programme
Start Date
End Date
Total Funding
€ 221 370
European Countries Involved

ALzheimer COoperative Valuation in Europe

The JA will be contribute to public health programmes in Europe and develop Alzheimers disease (AD) and dementia prevention and care models in different European countries. The aim is to contribute to improvements in health by supporting and facilitating quality and efficiency of public health and healthcare policies and interventions. Synergy and...

Funding Programme
Start Date
End Date
Total Funding
€ 613 100

Alzheimer Disease - gut connection

AD-gut

Alzheimer’s disease (AD) is the leading cause of dementia in the Western world and to date no cure nor any preventive strategy are available for this neurodegenerative disorder. Bacterial 16S rRNA sequencing from fecal samples revealed a remarkable shift in the gut microbiota of conventionally-raised AD mice compared to healthy, wild-type mice...

Funding Programme
Start Date
End Date
Total Funding
€ 7 686 620
European Countries Involved

Alzheimer’s disease data-driven insights on individual outcomes of importance

ADDITION

Alzheimer’s disease (AD) is the most common cause of dementia in the elderly, and a major reason for disability and death. The time course of AD varies between different people affected, and being able to tell in advance how the disease is likely to progress would have a great value for patient, their caregivers and for all of society. In the...

Funding Programme
Start Date
End Date
Total Funding
€ 1 100 000
European Countries Involved

Alzheimer’s Disease pathology within the ageing physiology

ADAGE

Everybody grows old. But while some people grow old in good health, others experience severe disease, such as Alzheimer's disease. Recent research demonstrates that Alzheimer's disease shares several features with the ageing process and suggests that the pathology is the consequence of something that goes wrong during physiological ageing...

Funding Programme
Start Date
End Date
Total Funding
€ 0
European Countries Involved

Amyloid imaging to Prevent Alzheimer’s Disease

AMYPAD

Beta-amyloid (β-amyloid) deposition is considered to be a necessary - but not sufficient - step on the path towards Alzheimer’s disease (AD). Depiction of brain β-amyloid in vivo can support an early diagnosis, and even provide an opportunity for consider secondary prevention of AD. Currently, however, the value of β-amyloid PET remains elusive...

Funding Programme
Start Date
End Date
Total Funding
€ 27 329 288

Biomarker based diagnosis of rapid progressive dementias – optimisation of diagnostic protocols.

DEMTEST

DEMTEST has established a large European and global collaboration between national surveillance units and dementia research centres, facilitating cooperation between neurologists, neuropathologists and neuroscientists. We work on standardisation of tests that are currently available and harmonise their use between centers worldwide. We define...

Funding Programme
Start Date
End Date
Total Funding
€ 2 200 000
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).